Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II

Shi, Vivian Y., Ingram, John R. ORCID: https://orcid.org/0000-0002-5257-1142, Lev-Tov, Hadar, Schneider-Burrus, Sylke, Forman, Seth, Porter, Martina L., Hayama, Koremasa, Thorlacius, Linnea, Lambert, Jérémy, Vaux, Tom, Lukowski, Bartosz, Rolleri, Robert L. and Szepietowski, Jacek C. 2025. Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II. Dermatology and Therapy 10.1007/s13555-025-01465-4

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (3MB)

Abstract

Introduction Hidradenitis suppurativa (HS) symptoms (pain, itch, odour and drainage) impair quality of life (QoL). Bimekizumab, a humanised IgG1 monoclonal antibody, selectively inhibits interleukin (IL)-17A and IL-17F. The impact of bimekizumab on patient-reported outcomes (PROs) was assessed using pooled 48-week data from BE HEARD I&II (BHI&II) studies in moderate to severe HS. Methods Patients received (initial/maintenance) bimekizumab 320 mg every 2 weeks (Q2W)/Q2W, bimekizumab Q2W/Q4W, bimekizumab Q4W/Q4W or placebo/bimekizumab Q2W. HS Symptom Daily Diary (HSSDD) and HS Symptom Questionnaire (HSSQ) captured HS-specific patient-reported symptoms; HS Quality of Life questionnaire (HiSQOL©) and Dermatology Life Quality Index (DLQI) captured health-related QoL (HRQoL). Change from baseline (CfB) and proportions of patients achieving clinically meaningful improvement thresholds or low disease impact are reported to Week 48 (observed case). Results Of 1014 randomised patients, 868 received bimekizumab and 146 placebo. Greater numerical reductions at Week 16 were observed across HSSDD/HSSQ scores with bimekizumab vs placebo. From Week 16 to 48, HSSQ scores further numerically reduced with continuous bimekizumab and substantially reduced for placebo/bimekizumab switchers. At Week 16, bimekizumab showed numerically greater improvement in HRQoL vs placebo (HiSQOL total score mean CfB: − 11.7 to − 10.3 vs − 5.5). HiSQOL response rate (21-point total score reduction) was numerically higher by Week 4 in bimekizumab-treated patients (17.2–21.4%) vs placebo (9.2%); rates increased to Week 48 with continuous bimekizumab (42.0–47.4%) and in switchers (55.0%). Patients with very severe disease impact (HiSQOL total score ≥ 24) decreased over time with bimekizumab. At Week 16, DLQI minimal clinically important difference (4-point decrease) achievement was numerically greater with bimekizumab vs placebo (54.9–64.6% vs 49.1%). Achievement increased to Week 48 and switchers attained similar proportions (63.5–74.5% vs 76.5%). Comparable trends were observed for DLQI score of 0/1 (no HRQoL impact) achievement rates. Conclusion Bimekizumab demonstrated clinically meaningful improvements by Week 4 in HRQoL, which were maintained over 1 year across PROs in patients with moderate to severe HS.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine
Publisher:	Springer
ISSN:	2193-8210
Date of First Compliant Deposit:	14 July 2025
Date of Acceptance:	4 June 2025
Last Modified:	16 Jul 2025 15:30
URI:	https://orca.cardiff.ac.uk/id/eprint/179769

Actions (repository staff only)

Edit Item